You are here
Open-Label, Extended-Use Study of Xerecept Initiated
This extended-use program will collect safety information and allow the treating physicians to attempt a maximum dexamethasone reduction and possible elimination altogether. XERECEPT will be provided to patients until either the drug becomes commercially available or if NTI research in this indication is discontinued.
Dr. Lisa U. Carr, Sr. Vice President and Chief Medical Officer of NTI, said, "We are pleased to offer the extended-use of this potential dexamethasone-sparing agent to patients in all of our trials."
Source: Neurobiological Technologies, Inc.